Resilient Argenx stock holds above $1,020 as Forte deal and Vyvgart growth lift outlook
Published on 08/29/2026 at 08:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx SE (ISIN NL0010832176) stock has been trading above $1,020 in late August 2026 after touching a new 52-week high close to $1,058 on August 27, 2026, helped by strong Vyvgart sales and the completed acquisition of Forte Biosciences.
Per recent coverage dated August 27, 2026, Argenx shares on Nasdaq closed at $1,058.30 that day, up from a 200-day moving average of $831.06, underscoring how the rally has extended far beyond the longer-term trend line.
For investors, the combination of organic growth in Vyvgart and the strategic Forte Biosciences deal is now central to the Argenx stock story.
Shares test fresh highs after Forte Biosciences acquisition
According to a detailed market report on August 27, 2026, Argenx stock on Nasdaq traded as high as $1,061.13 during that session before closing at $1,058.30, with a market capitalization of $66.20 billion and trading volume of 117,743 shares.
The same report noted that the stock price of $1,058.30 sat well above the 200-day moving average of $831.06, indicating a strong upward trend and a wide gap of $227.24 between the latest close and the long-term average.
In parallel on the European side, a Brussels quote overview showed the Euronext Brussels listing at EUR 895.20 on August 28, 2026, down 1.34 percent from EUR 907.40 the prior day, while performance for the ongoing year stood at a gain of 24.67 percent.
Another analysis of the Brussels line highlighted that Argenx shares recently touched a historic intraday high of EUR 913.00, surpassing a previous record of EUR 911.40 from August 26 and breaking through a resistance level at EUR 907.40 before easing back later in the session.
This cross-market picture means Argenx stock has been trading near record levels in both dollars and euros, reflecting sustained investor confidence despite some short-term volatility and profit taking.
Vyvgart growth and Q2 2026 earnings beat set the tone
The stock strength has been supported by robust fundamentals in the latest reporting period, with a recent earnings summary for the second quarter of 2026 citing earnings per share of $7.32 on revenue of $1.54 billion, compared with consensus expectations of $5.86 EPS and $1.45 billion in revenue.
That translates into an EPS beat of $1.46, while revenue exceeded the analyst consensus by $90 million, reinforcing the view that Argenx continues to execute ahead of expectations in its core autoimmune franchise.
Beyond the quarterly snapshot, an industry feature on Argenx highlighted that Vyvgart, the company’s flagship drug for autoimmune diseases, generated more than $2.8 billion in sales during the first half of 2026, representing a growth rate of more than 60 percent over the prior year period.
The same feature pointed out that Argenx recently completed a $2.2 billion acquisition of Forte Biosciences, a deal that brings an anti-CD122 antibody asset known as FB102 with clinical data in conditions such as vitiligo and celiac disease.
By integrating Forte Biosciences and adding FB102 to its pipeline, Argenx is expanding beyond its established indications for Vyvgart and positioning itself for a broader portfolio in autoimmune and inflammatory diseases.
From a valuation perspective, one Brussels-focused data page noted a latest closing price equivalent of 1,057.08 USD and an average analyst price target of 1,124.35 USD for the stock, implying potential upside of 67.27 USD from that translated level based on current consensus.
Analyst stance and recent rating actions
Recent analyst commentary captured in the same late August 2026 reporting set shows that the overall consensus view on Argenx shares remains at Moderate Buy, coupled with a consensus price target of $1,157.50.
Within that framework of positive yet selective coverage, some banks have raised their individual price targets, with one firm lifting its target to $1,415 and another upgrading the stock to a buy rating, signaling growing confidence in the long-term earnings trajectory.
At the same time, other outlets have noted short-term caution and described Argenx stock as a rich valuation case, referencing a 210 percent multi-year performance on the Brussels listing and underscoring that investors are paying for strong growth and pipeline optionality.
A separate analyst alert dated August 29, 2026 mentioned Argenx stock opening at $1,023.21 in the latest US trading session, which sits below the recent high of $1,058.30 but still comfortably within the upper end of the stock’s 52-week trading range.
Taken together, the earnings beat, Vyvgart’s sales momentum, and the expanded pipeline from Forte Biosciences are key factors underpinning the Moderate Buy consensus, even as some analysts flag valuation risks after the sharp run-up.
Clinical momentum in autoimmune myositis supports the pipeline
On the clinical front, multiple pieces of coverage from mid August 2026 reported positive topline results from a Phase 3 trial of efgartigimod, marketed as Vyvgart, in autoimmune myositis.
One such report emphasized that the Phase 3 ALKIVIA trial met its main goal in autoimmune myositis, opening the door for Argenx to pursue regulatory filings in another indication that could represent a sizeable new market opportunity.
A market news roundup on August 17, 2026 described the trial outcome as a key milestone and noted that Argenx was now eyeing a filing pathway in autoimmune myositis on the back of the successful study, further diversifying the label expansion strategy around Vyvgart.
Earlier communications from the company around the second quarter 2026 results had highlighted that important registration study readouts were expected in the second half of the year, pointing specifically to indications such as autoimmune myositis as part of the upcoming clinical news flow.
This clinical momentum, coupled with the existing commercial footprint of Vyvgart in myasthenia gravis and other autoimmune diseases, reinforces the narrative that Argenx is building a multi-indication franchise rather than relying on a single narrow market.
For investors assessing Argenx stock, the pace of label expansion and the success of Phase 3 programs like ALKIVIA are likely to be as important as short-term quarterly metrics when judging the sustainability of the company’s growth.
Representative product: Vyvgart in autoimmune diseases
Vyvgart is the centerpiece of Argenx’s commercial portfolio, targeting autoimmune diseases by modulating the neonatal Fc receptor to reduce pathogenic IgG antibodies.
In myasthenia gravis, Vyvgart has already become an established therapy, and first half 2026 sales of more than $2.8 billion underscore how quickly physicians have adopted the drug across geographies and lines of therapy.
The recent positive Phase 3 data in autoimmune myositis suggests that Vyvgart could add another high-value indication, complementing its existing uses and potentially supporting a longer growth runway as new patient populations become eligible for treatment.
Beyond these core indications, Vyvgart is being studied in a range of other autoimmune conditions, and the addition of Forte Biosciences’ FB102 asset further broadens Argenx’s ambitions in immune-mediated diseases.
Argenx stock at elevated levels heading into the next quarter
Argenx shares trade primarily on Nasdaq under the ticker ARGX, and as of August 27, 2026, the last reported closing price stood at $1,058.30, with a market capitalization of $66.20 billion.
That late August close sits above the stock’s 200-day moving average of $831.06 and near the higher end of the noted 52-week trading range referenced in global quote data, underscoring how the market is pricing in both strong current results and future pipeline potential.
Looking ahead, the next scheduled earnings date is October 22, 2026, giving Argenx several weeks for further clinical and strategic updates to influence sentiment before the next set of quarterly numbers.
Read more
Corporate news on Argenx 52-week high
Fact box
Company: Argenx SE
ISIN: NL0010832176
Ticker: ARGX
Exchange: Nasdaq
Price (as of August 27, 2026, 4:00 p.m. ET): $1,058.30 USD
Market cap: $66.20 billion (as of August 27, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq-100
Next earnings date: October 22, 2026
